The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells

Carcinogenesis

Volumn 32, Issue 11, 2011, Pages 1634-1640

  Shin, Masashi ^a,f   Matsuo, Kou ^a   Tada, Takeyuki ^b   Fukushima, Hidefumi ^a   Furuta, Hiroyuki ^a   Ozeki, Satoru ^b   Kadowaki, Tomoko ^c   Yamamoto, Kenji ^d   Okamoto, Masato ^e   Jimi, Eijiro ^a  

^a KYUSHU DENTAL COLLEGE   (Japan)

^b FUKUOKA DENTAL COLLEGE   (Japan)

^c NAGASAKI UNIVERSITY   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE METASTASIS; CANCER CELL; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MOUTH CARCINOMA; NONHUMAN; NUDE MOUSE; OSTEOCLAST; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BONE NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CELL MOVEMENT; CELL PROLIFERATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MALE; MANDIBULAR NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOUTH NEOPLASMS; NEOPLASM INVASIVENESS; NF-KAPPA B; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 80755168375     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr198     Document Type: Article

References (41)

1. Jordan, R.C. et al. (1997) Oral squamous cell carcinoma: new insights. J. Can. Dent. Assoc., 63, 517-518, 521-525.
2. Hicks, W.L.Jr. et al. (1997) Squamous cell carcinoma of the floor of mouth: a 20-year review. Head Neck, 19, 400-405.
3. Brown, J.S. et al. (2002) Patterns of invasion and routes of tumor entry into the mandible by oral squamous cell carcinoma. Head Neck, 24, 370-383.
4. Wong, R.J. et al. (2000) Histological pattern of mandibular invasion by oral squamous cell carcinoma. Laryngoscope, 110, 65-72.
5. Suda, T. et al. (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev., 20, 345-357.
6. Nakashima, T. et al. (2003) RANKL and RANK as novel therapeutic targets for arthritis. Curr. Opin. Rheumatol., 15, 280-287.
7. Boyle, W.J. et al. (2003) Osteoclast differentiation and activation. Nature, 423, 337-342.
8. Yasuda, H. et al. (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA, 95, 3597-3602.
9. Lacey, D.L. et al. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 93, 165-176.
10. Tsuda, E. et al. (1997) Isolation of a novel cytokine fromhuman fibroblasts that specifically inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun., 234, 137-142.
11. Simonet, W.S. et al. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 89, 309-319.
12. Guise, T.A. et al. (1998) Cancer and bone. Endocr. Rev., 19, 18-54.
13. Bendre, M. et al. (2003) Breast cancer metastasis to bone: it is not all about PTHrP. Clin. Orthop. Relat. Res., 415 (Suppl), S39-S45.
14. Thomas, R.J. et al. (1999) Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology, 140, 4451-4458.
15. Lin, D.L. et al. (2001) Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate, 47, 212-221.
16. Brown, J.M. et al. (2001) Osteoprotegerin and rank ligand expression in prostate cancer. Urology, 57, 611-616.
17. Sezer, O. et al. (2003) RANK ligand and osteoprotegerin in myeloma bone disease. Blood, 101, 2094-2098.
18. Yaccoby, S. et al. (2004) Cancer and the microenvironment: myelomaosteoclast interactions as a model. Cancer Res., 64, 2016-2023.
19. Nagai, M. et al. (2000) Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation. Biochem. Biophys. Res. Commun., 269, 532-536.
20. Farrugia, A.N. et al. (2003) Receptor activator of nuclear factor-jB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res., 63, 5438-5445.
21. Giuliani, N. et al. (2001) Myeloma cells induce imbalance in the osteoprotegerin/ osteoprotegerin ligand system in the human bone marrow environment. Blood, 98, 3527-3533.
22. Ohshiba, T. et al. (2003) Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis. Br. J. Cancer, 88, 1318-1326.
23. Tada, T. et al. (2005) Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts. Int. J. Cancer, 116, 253-262.
24. Tada, T. et al. (2009) Oral squamous cell carcinoma cells modulate osteoclast function by RANKL-dependent and -independent mechanisms. Cancer Lett., 274, 126-131.
25. Jones, D.H. et al. (2006) Regulation of cancer cell migration and bone metastasis by RANKL. Nature, 440, 692-696.
26. Armstrong, A.P. et al. (2008) RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate, 68, 92-104.
27. Sabbota, A.L. et al. (2010) Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration. Cancer Res., 70, 5558-5566.
28. Azuma, M. et al. (2003) Sisplatin induces apoptosis in oral squamous carcinoma cells by the mitochondria-mediated but not the NF-jB-suppressed pathway. Oral Oncol., 39, 282-289.
29. Shin, M. et al. (2007) Association of cathepsin E with tumor growth arrest through angiogenesis inhibition and enhanced immune responses. Biol. Chem., 388, 1173-1181.
30. Jimi, E. et al. (2004) Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med., 10, 617-624.
31. Okamoto, M. et al. (2000) Mechanism for bone invasion of oral cancer cells mediated by interleukin-6 in vitro and in vivo. Cancer, 89, 1966-1975.
32. Roodman, G.D. et al. (2008) RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat. Rev., 34, 92-101.
33. Kayamori, K. et al. (2010) Roles of interleukin-6 and parathyroid hormonerelated peptide in osteoclast formation associated with oral cancers: significance of interleukin-6 synthesized by stromal cells in response to cancer cells. Am. J. Pathol., 176, 968-980.
34. Tan, W. et al. (2011) Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature, 470, 548-553.
35. Hauschka, P.V. et al. (1983) Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J. Biol. Chem., 261, 12665-12674.
36. Pfeilschifter, J. et al. (1987) Modulation of type b transforming growth factor activity in bone culture by osteotropic hormones. Proc. Natl. Acad. Sci. USA, 84, 2024-2028.
37. Pogrel, M.A. (2004) Bisphosphonates and bone necrosis. J. Oral Maxillofac. Surg., 63, 391-392.
38. Dannemann, C. et al. (2007) Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder. Bone, 40, 828-834.
39. Allen, M.R. et al. (2008) Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J. Oral Maxillofac. Surg., 66, 987-994.
40. Body, J.J. et al. (2003) A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer, 97, 887-892.
41. Bekker, P.J. et al. (2001) The effect of a single dose of osteoprotegerin in postmenopausal women. J. Bone Miner. Res., 16, 348-360.